Summary
President Donald Trump announced a 100 percent tariff on imported pharmaceutical drugs, which will double their prices for U.S. importers and consumers. An exception exists for companies building pharmaceutical plants in the U.S. The announcement impacted the stock market, causing a drop in the share prices of several pharmaceutical companies across Asia and Europe.
Key Facts
- President Trump announced a 100 percent import tax on branded or patented pharmaceutical products starting October 1.
- The tariff will double the cost of these imported drugs for U.S. importers and consumers.
- Companies building pharmaceutical manufacturing plants in the U.S. are exempt from the tariff.
- In 2023, the U.S. imported approximately $158 billion worth of pharmaceutical products.
- Major pharmaceutical import sources include Ireland, Switzerland, Germany, and India.
- The announcement led to a drop in share prices for various pharmaceutical companies in Asia and Europe.
- Indian pharmaceutical companies might not be heavily affected as they mainly supply generics, not targeted by the new tariffs.
